<DOC>
	<DOC>NCT01885676</DOC>
	<brief_summary>- Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals. - This clinical trial was designed to evaluate the efficacy and safety of using a preparation of autologous plasma rich in growth factors (PRGF-Endoret) in the treatment of androgenetic alopecia.</brief_summary>
	<brief_title>Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Androgenetic alopecia according to the following scales: Men: Hamilton/Norwood Scale: grades IIVI Women: Ludwig Scale grades III. Possibility of followup during the study No androgenetic alopecia Telogen and anagen effluvium Active inflammation or infection in the intervention area Presence of active systemic infections. Background of cancerous or precancerous lesions. Background of connective or rheumatic diseases. Suffering from any serious blood disorders. To have undergone treatments for alopecia in the previous 6 months. Previous hair implants Intake of drugs that affect hair loss. Be undergoing immunosuppressive therapy and/or anticoagulants. Known intolerance to mesotherapy. Taking contraceptives containing cyproterone acetate. Pregnancy In general, any limitations that would prevent the proper application of both treatments and the right monitoring of the efficacy variables.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>